Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.
Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. Strickler JH, et al. Among authors: yoshino t. Future Oncol. 2024 Dec 26:1-9. doi: 10.1080/14796694.2024.2441101. Online ahead of print. Future Oncol. 2024. PMID: 39723627 Free article.
A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device.
Bando H, Naito Y, Yamada T, Fujisawa T, Imai M, Sakamoto Y, Saigusa Y, Yamamoto K, Tomioka Y, Takeshita N, Sunami K, Futamura M, Notake C, Aoki S, Okano K, Yoshino T. Bando H, et al. Among authors: yoshino t. Int J Clin Oncol. 2024 Dec 23. doi: 10.1007/s10147-024-02684-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39714567 Review.
Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zuo Y, Fogelman D, Adelberg D, Diaz LA Jr. André T, et al. Among authors: yoshino t. Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.11.012. Online ahead of print. Ann Oncol. 2024. PMID: 39631622
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer.
Lee SH, Menis J, Kim TM, Kim HR, Zhou C, Kurniawati SA, Prabhash K, Hayashi H, Lee DD, Imasa MS, Teh YL, Yang JC, Reungwetwattana T, Sriuranpong V, Wu CE, Ang Y, Sabando M, Thiagarajan M, Mizugaki H, Noronha V, Yulianti M, Zhang L, Smyth E, Yoshino T, Park JO, Pentheroudakis G, Park S, Peters S, Ahn JB, Popat S. Lee SH, et al. Among authors: yoshino t. ESMO Open. 2024 Dec;9(12):103996. doi: 10.1016/j.esmoop.2024.103996. Epub 2024 Nov 29. ESMO Open. 2024. PMID: 39615406 Free PMC article.
MS-DIAL 5 multimodal mass spectrometry data mining unveils lipidome complexities.
Takeda H, Matsuzawa Y, Takeuchi M, Takahashi M, Nishida K, Harayama T, Todoroki Y, Shimizu K, Sakamoto N, Oka T, Maekawa M, Chung MH, Kurizaki Y, Kiuchi S, Tokiyoshi K, Buyantogtokh B, Kurata M, Kvasnička A, Takeda U, Uchino H, Hasegawa M, Miyamoto J, Tanabe K, Takeda S, Mori T, Kumakubo R, Tanaka T, Yoshino T, Okamoto M, Takahashi H, Arita M, Tsugawa H. Takeda H, et al. Among authors: yoshino t. Nat Commun. 2024 Nov 28;15(1):9903. doi: 10.1038/s41467-024-54137-w. Nat Commun. 2024. PMID: 39609386 Free PMC article.
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. Among authors: yoshino t. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: yoshino t. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.
2,109 results